Decrease of receptor detectibility following CRAD replication in a small fraction of cells. by Johan Rebetz (255622)

A blue-shifted fluorescence donor increases fAP amplitude but exhibits a decreased SNR. A. by Ann E. Fink (312543)

Gefitinib and erlotinib decreased cyclin-D1 without activation of caspase-3. by Satoshi Koyama (784927)

Decrease of goblet cells in mice fed a high-fat diet (HFD). by June-Chul Lee (2850536)

Decrease of Paneth cells in mice fed a high-fat diet (HFD). by June-Chul Lee (2850536)

PV1-treated mice exhibited a decrease in overall activation of T lymphocytes. by Pedro Henrique Papotto (791904)

V3Nter decreases colony formation and induces tumor cell death in HCT116 and HepG2 cells. by Delphine Quélard (43727)

Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection. by Blake A. Shannon (14197601)

Administration of γPGA attenuates Th2 immune responses elicited by the cysteine protease papain through a decrease in basophils. by Hyun Jung Park (116737)

Decreased numbers of motor neurons in Tc1 and Dp(16)1Yey mice. by Sheona Watson-Scales (586942)

PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

Decreased Fhl1b activity augments induction of pancreatic endocrine cells. by Jin Xu (31283)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

RNF5 loss decreases ERK and Akt activation, CDK1 and Smo expression and KSHV lytic replication in PEL cells. by Xiaojuan Li (351842)

Decreased expression levels of the MYO6 protein in <i>ksv</i> mice. by Yuta Seki (4385833)

“…Expression of MYO6 is completely ablated in the hair cells of <i>Myo6</i>^-/- mice (C). Scale bar = 5 μm. D and E. Western blot analysis of homogenates prepared from the inner ears of +/+, +/<i>ksv</i> and <i>ksv/ksv</i> mice at P30 detected with anti-MYO6 (N-ter, D) and MYO6 (C-ter, E) antibodies (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0183477#pone.0183477.s007" target="_blank">S2 Table</a>). …”

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects: